You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEverolimus
Accession NumberDB01590
TypeSmall Molecule
GroupsApproved
DescriptionEverolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Structure
Thumb
Synonyms
40-O-(2-hydroxyethyl)-rapamycin
External IDs RAD 666 / RAD-001 / RAD-666 / RAD001 / SDZ RAD / SDZ-RAD
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AfinitorTablet10 mgOralNovartis Europharm Limited  2009-08-03Not applicableEu
AfinitorTablet10 mgOralNovartis Europharm Limited  2009-08-03Not applicableEu
AfinitorTablet5 mgOralNovartis2010-03-15Not applicableCanada
AfinitorTablet5 mgOralNovartis Europharm Limited  2009-08-03Not applicableEu
AfinitorTablet10 mgOralNovartis2010-01-19Not applicableCanada
AfinitorTablet5 mg/1OralNovartis2009-03-31Not applicableUs
AfinitorTablet7.5 mgOralNovartis2016-04-05Not applicableCanada
AfinitorTablet10 mgOralNovartis Europharm Limited  2009-08-03Not applicableEu
AfinitorTablet2.5 mgOralNovartis2011-08-05Not applicableCanada
AfinitorTablet10 mg/1OralNovartis2009-03-31Not applicableUs
AfinitorTablet5 mgOralNovartis Europharm Limited  2009-08-03Not applicableEu
AfinitorTablet2.5 mgOralNovartis Europharm Limited  2009-08-03Not applicableEu
AfinitorTablet2.5 mg/1OralNovartis2010-07-09Not applicableUs
AfinitorTablet5 mgOralNovartis Europharm Limited  2009-08-03Not applicableEu
AfinitorTablet2.5 mgOralNovartis Europharm Limited  2009-08-03Not applicableEu
AfinitorTablet7.5 mg/1OralNovartis2011-07-29Not applicableUs
Afinitor DisperzTablet, for suspension5 mg/1OralNovartis2012-08-29Not applicableUs
Afinitor DisperzTablet, for suspension5 mgOralNovartis2014-11-28Not applicableCanada
Afinitor DisperzTablet, for suspension2 mg/1OralNovartis2012-08-29Not applicableUs
Afinitor DisperzTablet, for suspension2 mgOralNovartis2014-11-28Not applicableCanada
Afinitor DisperzTablet, for suspension3 mg/1OralNovartis2012-08-29Not applicableUs
Afinitor DisperzTablet, for suspension3 mgOralNovartis2014-11-28Not applicableCanada
CerticanTablet0.25 mgOralNovartisNot applicableNot applicableCanada
CerticanTablet0.50 mgOralNovartisNot applicableNot applicableCanada
CerticanTablet0.75 mgOralNovartisNot applicableNot applicableCanada
VotubiaTablet10 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet2.5 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet, for suspension3 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet10 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet2.5 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet, for suspension3 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet10 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet2.5 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet, for suspension5 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet, for suspension2 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet, for suspension5 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet5 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet, for suspension2 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet5 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
VotubiaTablet, for suspension2 mgOralNovartis Europharm Limited  2011-09-02Not applicableEu
ZortressTablet.5 mg/1OralNovartis2010-04-22Not applicableUs
ZortressTablet.75 mg/1OralNovartis2010-04-22Not applicableUs
ZortressTablet.25 mg/1OralNovartis2010-04-22Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
VotubiaNovartis
Brand mixturesNot Available
Categories
UNII9HW64Q8G6G
CAS number159351-69-6
WeightAverage: 958.24
Monoisotopic: 957.581356357
Chemical FormulaC53H83NO14
InChI KeyHKVAMNSJSFKALM-GKUWKFKPSA-N
InChI
InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
IUPAC Name
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0⁴,⁹]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
SMILES
[H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[[email protected]](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[[email protected]](C)C[[email protected]](C)\C=C\C=C\C=C(C)\[[email protected]](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Pharmacology
IndicationEverolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionEverolimus is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor. The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake.
TargetKindPharmacological actionActionsOrganismUniProt ID
Serine/threonine-protein kinase mTORProteinyes
inhibitor
HumanP42345 details
Related Articles
AbsorptionIn patients with advanced solid tumors, peak everolimus concentrations are reached 1 to 2 hours after administration of oral doses ranging from 5 mg to 70 mg. Following single doses, Cmax is dose-proportional between 5 mg and 10 mg. At doses of 20 mg and higher, the increase in Cmax is less than dose-proportional, however AUC shows dose-proportionality over the 5 mg to 70 mg dose range. Steady-state was achieved within 2 weeks following once-daily dosing. Dose Proportionality in Patients with SEGA (subependymal giant-cell astrocytomas) and TSC (tuberous sclerosis complex): In patients with SEGA and TSC, everolimus Cmin was approximately dose-proportional within the dose range from 1.35 mg/m2 to 14.4 mg/m2.
Volume of distribution

The blood-to-plasma ratio of everolimus is 17% to 73%.

Protein binding~ 74% in both healthy patients and those with moderate hepatic impairment.
Metabolism

Everolimus is a substrate of CYP3A4 and PgP (phosphoglycolate phosphatase). Three monohydroxylated metabolites, two hydrolytic ring-opened products, and a phosphatidylcholine conjugate of everolimus were the 6 primary metabolites detected in human blood. In vitro, everolimus competitively inhibited the metabolism of CYP3A4 and was a mixed inhibitor of the CYP2D6 substrate dextromethorphan.

Route of eliminationAfter a single dose of radiolabeled everolimus was given to transplant patients receiving cyclosporine, the majority (80%) of radioactivity was recovered from the feces and only a minor amount (5%) was excreted in urine.
Half life~30 hours.
Clearance

Following a 3 mg radiolabeled dose of everolimus, 80% of the radioactivity was recovered from the feces, while 5% was excreted in the urine.

ToxicityIC50 of 0.63 nM.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Everolimus.Approved, Investigational
AcetaminophenThe serum concentration of Everolimus can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Everolimus.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Everolimus.Approved
AfatinibThe serum concentration of Everolimus can be increased when it is combined with Afatinib.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Everolimus.Experimental
AlbendazoleThe serum concentration of Everolimus can be increased when it is combined with Albendazole.Approved, Vet Approved
AlectinibThe serum concentration of Everolimus can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Everolimus can be increased when it is combined with Alfentanil.Approved, Illicit
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Everolimus.Approved
AmantadineThe serum concentration of Everolimus can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Everolimus can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Everolimus can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Everolimus can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Everolimus can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Everolimus can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Everolimus can be increased when it is combined with Amsacrine.Approved
AprepitantThe serum concentration of Everolimus can be increased when it is combined with Aprepitant.Approved, Investigational
AstemizoleThe serum concentration of Everolimus can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Everolimus can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Everolimus can be increased when it is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Everolimus can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Everolimus can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Everolimus can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Everolimus can be increased when it is combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Everolimus.Investigational
BCGThe therapeutic efficacy of Bcg can be decreased when used in combination with Everolimus.Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Benazepril.Approved, Investigational
BenzocaineThe serum concentration of Everolimus can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Everolimus can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Everolimus.Approved, Investigational
BexaroteneThe serum concentration of Everolimus can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Everolimus can be increased when it is combined with Biperiden.Approved
BoceprevirThe serum concentration of Everolimus can be increased when it is combined with Boceprevir.Approved
BortezomibThe serum concentration of Everolimus can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Everolimus can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Everolimus can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Everolimus can be increased when it is combined with Bromocriptine.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Everolimus.Withdrawn
BuprenorphineThe serum concentration of Everolimus can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Everolimus can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Everolimus can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Everolimus can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Everolimus can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Everolimus can be increased when it is combined with Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Everolimus is combined with Candoxatril.Experimental
CaptoprilThe serum concentration of Everolimus can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Everolimus can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Everolimus can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Everolimus can be increased when it is combined with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Everolimus.Experimental
CeritinibThe serum concentration of Everolimus can be increased when it is combined with Ceritinib.Approved
ChloroquineThe serum concentration of Everolimus can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Everolimus can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Everolimus can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Everolimus can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Everolimus can be increased when it is combined with Cholesterol.Experimental
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Everolimus.Experimental
CilazaprilThe serum concentration of Everolimus can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Everolimus can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Everolimus can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Everolimus can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Everolimus can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Everolimus can be increased when it is combined with Clemastine.Approved
ClofazimineThe serum concentration of Everolimus can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Everolimus can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Everolimus can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Everolimus is combined with Clozapine.Approved
CobicistatThe serum concentration of Everolimus can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Everolimus can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Everolimus can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Everolimus can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Everolimus can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Everolimus can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Everolimus can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Everolimus can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Everolimus can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Everolimus can be increased when it is combined with Dactinomycin.Approved
DarunavirThe serum concentration of Everolimus can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Everolimus can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Everolimus can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Everolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Everolimus can be increased when it is combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Everolimus.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Everolimus.Investigational
DesipramineThe serum concentration of Everolimus can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Everolimus.Approved
DesloratadineThe serum concentration of Everolimus can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Everolimus can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Everolimus can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Everolimus can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Everolimus.Approved
DigoxinThe serum concentration of Everolimus can be increased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Everolimus can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Everolimus can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Everolimus can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Everolimus.Approved, Investigational
DoxazosinThe serum concentration of Everolimus can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Everolimus can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Everolimus can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Everolimus can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Everolimus can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Everolimus can be increased when it is combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Everolimus.Approved
EfavirenzThe serum concentration of Everolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Everolimus can be increased when it is combined with Elbasvir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.Approved
EnalaprilThe serum concentration of Everolimus can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Enalaprilat.Approved
EnzalutamideThe serum concentration of Everolimus can be decreased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Everolimus can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Everolimus can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Everolimus can be increased when it is combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Everolimus can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstramustineThe serum concentration of Everolimus can be increased when it is combined with Estramustine.Approved
EtoposideThe serum concentration of Everolimus can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Everolimus can be increased when it is combined with Etravirine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Everolimus.Approved, Investigational
FelodipineThe serum concentration of Everolimus can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Everolimus can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Everolimus can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Everolimus can be increased when it is combined with Fidaxomicin.Approved
FingolimodEverolimus may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Everolimus can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Everolimus can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Everolimus can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Everolimus can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Everolimus can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Everolimus can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Everolimus can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Everolimus can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril.Approved
FosphenytoinThe serum concentration of Everolimus can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Everolimus can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Everolimus is combined with G17DT.Investigational
GefitinibThe serum concentration of Everolimus can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of Everolimus can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Everolimus is combined with GI-5005.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Everolimus.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Everolimus.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Everolimus.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Everolimus.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Everolimus.Approved
GlyburideThe serum concentration of Everolimus can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Everolimus can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Everolimus can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Everolimus can be increased when it is combined with Grepafloxacin.Withdrawn
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Everolimus.Investigational
HaloperidolThe serum concentration of Everolimus can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Everolimus can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Everolimus can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Everolimus can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Imidapril.Investigational
ImipramineThe serum concentration of Everolimus can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Everolimus can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Everolimus can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Everolimus is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Everolimus is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Everolimus.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Everolimus.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Everolimus.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Everolimus.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Everolimus.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Everolimus.Approved
IsavuconazoniumThe serum concentration of Everolimus can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsradipineThe serum concentration of Everolimus can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Everolimus can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Everolimus can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Everolimus can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Everolimus can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Everolimus can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Everolimus can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Everolimus can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Everolimus is combined with Leflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Everolimus can be increased when it is combined with Levofloxacin.Approved, Investigational
LidocaineThe serum concentration of Everolimus can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Everolimus.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Everolimus.Approved
LisinoprilThe serum concentration of Everolimus can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Everolimus can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Everolimus can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Everolimus can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Everolimus can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Everolimus can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Everolimus can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Everolimus can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Everolimus can be decreased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Everolimus can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Everolimus can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Everolimus can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Everolimus can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Everolimus can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Everolimus.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus.Approved
MethadoneThe serum concentration of Everolimus can be increased when it is combined with Methadone.Approved
MetoprololThe serum concentration of Everolimus can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Everolimus can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Everolimus can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Everolimus can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Everolimus can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Everolimus.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Everolimus.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Everolimus.Approved, Investigational
MitomycinThe serum concentration of Everolimus can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Everolimus can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Everolimus can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Everolimus can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Moexipril.Approved
MorphineThe serum concentration of Everolimus can be increased when it is combined with Morphine.Approved, Investigational
NafcillinThe serum concentration of Everolimus can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Everolimus can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Everolimus can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Everolimus is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Everolimus.Approved, Investigational
NefazodoneThe serum concentration of Everolimus can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Everolimus can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Everolimus can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Everolimus can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Everolimus can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Everolimus can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Everolimus can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Everolimus can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Everolimus can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Everolimus can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Everolimus can be increased when it is combined with Nitrendipine.Approved
OlaparibThe serum concentration of Everolimus can be increased when it is combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Everolimus.Experimental
OmapatrilatThe risk or severity of adverse effects can be increased when Everolimus is combined with Omapatrilat.Investigational
OmeprazoleThe serum concentration of Everolimus can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Everolimus can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Everolimus.Approved
P-NitrophenolThe serum concentration of Everolimus can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Everolimus can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Everolimus can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Everolimus can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Everolimus can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Everolimus can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe serum concentration of Everolimus can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Everolimus can be increased when it is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Everolimus.Approved, Withdrawn
PhenobarbitalThe serum concentration of Everolimus can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Everolimus can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Everolimus.Approved, Investigational
PimozideThe serum concentration of Everolimus can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Everolimus.Approved, Investigational
PonatinibThe serum concentration of Everolimus can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Everolimus can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Everolimus.Approved, Investigational
PravastatinThe serum concentration of Everolimus can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Everolimus can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Everolimus can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Everolimus can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Everolimus can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Everolimus can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Everolimus can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Everolimus can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Everolimus can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Everolimus can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Everolimus can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Everolimus can be increased when it is combined with Quinacrine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Everolimus can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Everolimus can be increased when it is combined with Quinine.Approved
Rabies vaccineThe risk or severity of adverse effects can be increased when Everolimus is combined with Rabies vaccine.Approved
Rabies vaccineThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Everolimus.Approved
RamiprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Ramipril.Approved
RanitidineThe serum concentration of Everolimus can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Everolimus can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Everolimus can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Everolimus can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Everolimus.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Everolimus is combined with Rescinnamine.Approved
ReserpineThe serum concentration of Everolimus can be increased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Everolimus can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Everolimus can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Everolimus can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Everolimus can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Everolimus is combined with CDX-110.Investigational
RitonavirThe serum concentration of Everolimus can be increased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Everolimus.Approved
RolapitantThe serum concentration of Everolimus can be increased when it is combined with Rolapitant.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Everolimus.Approved, Investigational
SaquinavirThe serum concentration of Everolimus can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Everolimus.Approved
ScopolamineThe serum concentration of Everolimus can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Everolimus can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Everolimus can be increased when it is combined with Sertraline.Approved
SildenafilThe serum concentration of Everolimus can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Everolimus can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Everolimus can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Everolimus can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Everolimus.Approved
SirolimusThe serum concentration of Everolimus can be increased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Everolimus.Approved, Investigational
SorafenibThe serum concentration of Everolimus can be increased when it is combined with Sorafenib.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Spirapril.Approved
SpironolactoneThe serum concentration of Everolimus can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Everolimus is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Everolimus can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Everolimus can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Everolimus can be increased when it is combined with Stiripentol.Approved
SulfinpyrazoneThe serum concentration of Everolimus can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Everolimus can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Everolimus.Approved, Investigational
SumatriptanThe serum concentration of Everolimus can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Everolimus can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Everolimus can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Everolimus.Approved, Investigational
TacrolimusThe serum concentration of Everolimus can be increased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Everolimus can be increased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Everolimus can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Everolimus can be increased when it is combined with Telaprevir.Approved
TelithromycinThe serum concentration of Everolimus can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Everolimus can be increased when it is combined with Telmisartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Everolimus can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Everolimus can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Everolimus can be increased when it is combined with Terfenadine.Withdrawn
TestosteroneThe serum concentration of Everolimus can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Everolimus is combined with TG4010.Investigational
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Everolimus.Investigational
TicagrelorThe serum concentration of Everolimus can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Everolimus can be increased when it is combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Everolimus can be decreased when it is combined with Tocilizumab.Approved
TofacitinibEverolimus may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Everolimus.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Everolimus.Approved
TolvaptanThe serum concentration of Everolimus can be increased when it is combined with Tolvaptan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Everolimus is combined with Trandolapril.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Everolimus.Approved, Investigational
TrifluoperazineThe serum concentration of Everolimus can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Everolimus can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Everolimus can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Everolimus can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Everolimus.Withdrawn
TroleandomycinThe serum concentration of Everolimus can be increased when it is combined with Troleandomycin.Approved
VenlafaxineThe serum concentration of Everolimus can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Everolimus can be increased when it is combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Everolimus.Approved, Investigational
VinblastineThe serum concentration of Everolimus can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Everolimus can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Everolimus can be increased when it is combined with Vinorelbine.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Everolimus.Approved, Investigational
VoriconazoleThe serum concentration of Everolimus can be increased when it is combined with Voriconazole.Approved, Investigational
ZimelidineThe serum concentration of Everolimus can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Everolimus can be increased when it is combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference
  1. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001038/WC500022817.pdf
General References
  1. Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA: Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem. 2001 Jun 7;44(12):2027-34. [PubMed:11384247 ]
  2. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11. doi: 10.1056/NEJMoa1001671. [PubMed:21047224 ]
  3. den Burger JC, Wilhelm AJ, Chahbouni A, Vos RM, Sinjewel A, Swart EL: Analysis of cyclosporin A, tacrolimus, sirolimus, and everolimus in dried blood spot samples using liquid chromatography tandem mass spectrometry. Anal Bioanal Chem. 2012 Oct;404(6-7):1803-11. doi: 10.1007/s00216-012-6317-8. Epub 2012 Aug 17. [PubMed:22899246 ]
  4. Pawaskar DK, Straubinger RM, Fetterly GJ, Hylander BH, Repasky EA, Ma WW, Jusko WJ: Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemother Pharmacol. 2013 May;71(5):1231-40. doi: 10.1007/s00280-013-2117-x. Epub 2013 Mar 3. [PubMed:23455452 ]
External Links
ATC CodesL01XE10L04AA18
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (548 KB)
MSDSDownload (220 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingNot AvailableMeningiomas / Neurofibromatosis Type 2 / Vestibular Schwannomas1
0RecruitingTreatmentDelayed Graft Function1
1Active Not RecruitingOtherNasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentAdenoidcystic Carcinoma / Neuroendocrine Tumors / Solid Organ Malignancies1
1Active Not RecruitingTreatmentAdvanced Cancers / Tumors, Solid1
1Active Not RecruitingTreatmentCancer, Advanced1
1Active Not RecruitingTreatmentCancer, Advanced / Tumors, Solid2
1Active Not RecruitingTreatmentCarcinoma of the Prostate2
1Active Not RecruitingTreatmentEsophageal Cancers / Neoplasms, Esophageal1
1Active Not RecruitingTreatmentGastrinoma / Glucagonoma / Insulinoma / Metastatic Gastrointestinal Carcinoid Tumor / Metastatic Pheochromocytoma / Pancreatic Polypeptide Tumor / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Recurrent Melanoma / Recurrent Neuroendocrine Carcinoma of the Skin / Recurrent Non-small Cell Lung Cancer / Recurrent Pheochromocytoma / Recurrent Renal Cell Cancer / Somatostatinoma / Stage III Neuroendocrine Carcinoma of the Skin / Stage IV Melanoma / Stage IV Non-Small Cell Lung Cancer / Stage IV Renal Cell Cancer / Thyroid Gland Medullary Carcinoma / Unspecified Adult Solid Tumor, Protocol Specific1
1Active Not RecruitingTreatmentKidney Cancer / Tumors, Solid1
1Active Not RecruitingTreatmentLeukemias1
1Active Not RecruitingTreatmentLung Cancers / Tumors, Solid1
1Active Not RecruitingTreatmentLymphoma NOS1
1Active Not RecruitingTreatmentNeoplasm Metastases1
1Active Not RecruitingTreatmentNeoplasms1
1Active Not RecruitingTreatmentNeoplasms / Neoplasms, Breast / Neoplasms, Kidney / Pancreatic Neuroendocine Neoplasms1
1Active Not RecruitingTreatmentNeuroendocrine Tumors2
1Active Not RecruitingTreatmentRenal Cell Carcinoma (RCC)1
1CompletedNot AvailableHepatic Insufficiency1
1CompletedNot AvailableTumors, Solid1
1CompletedTreatmentAML1
1CompletedTreatmentAdvanced Cancer of the Esophagogastric Junction / Gastric cancer stage IV1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Solid Tumors / Metastatic Breast Cancer (MBC) / Metastatic Renal Cell Carcinoma1
1CompletedTreatmentBladder Cancers / Renal Pelvis Cancer / Ureter Cancer1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentCancer, Breast2
1CompletedTreatmentCancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCarcinoid Tumors / Neuroendocrine Tumors / Pancreatic Neuroendocrine Tumors (pNET)2
1CompletedTreatmentCarcinoma of the Prostate1
1CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1CompletedTreatmentCentral nervous system neoplasms malignant NEC / Recurrent or Refractory Solid Tumors1
1CompletedTreatmentCholangiocarcinoma of the Gallbladder / Localized Gallbladder Cancer / Unresectable Gallbladder Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)1
1CompletedTreatmentEndometrial Cancers1
1CompletedTreatmentGastric cancer stage IV1
1CompletedTreatmentGastrin-Producing Neuroendocrine Tumor / Lung Carcinoid Tumor / Metastatic Digestive System Neuroendocrine Tumor G1 / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Polypeptide Tumor / Paraganglioma / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Merkel Cell Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Regional Digestive System Neuroendocrine Tumor G1 / Somatostatin-Producing Neuroendocrine Tumor / Stage III Merkel Cell Carcinoma / Stage IV Merkel Cell Carcinoma / Thyroid Gland Medullary Carcinoma1
1CompletedTreatmentGlioblastomas / Gliosarcoma1
1CompletedTreatmentHEAD & NECK Cancer1
1CompletedTreatmentKidney Cancer / Renal Cell Carcinoma (RCC)1
1CompletedTreatmentKidney Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentLocally Advanced Cervical Cancer1
1CompletedTreatmentLung Cancers1
1CompletedTreatmentLung Neuroendocrine Neoplasm1
1CompletedTreatmentLymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentLymphoma NOS / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1CompletedTreatmentMetastatic Clear Cell Renal Cancer1
1CompletedTreatmentMetastatic Colorectal Cancers1
1CompletedTreatmentMetastatic Renal Cell Carcinoma1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentNeoplasms Metastasis / Neoplasms, Breast1
1CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)4
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Relapsed and/or Refractory Solid Tumors / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentRecurrent Adenoid Cystic Carcinoma of the Oral Cavity / Recurrent Basal Cell Carcinoma of the Lip / Recurrent Colon Cancer / Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Recurrent Lymphoepithelioma of the Nasopharynx / Recurrent Lymphoepithelioma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Recurrent Mucoepidermoid Carcinoma of the Oral Cavity / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Stage IV Adenoid Cystic Carcinoma of the Oral Cavity / Stage IV Basal Cell Carcinoma of the Lip / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Lymphoepithelioma of the Oropharynx / Stage IV Mucoepidermoid Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Verrucous Carcinoma of the Larynx / Stage IV Verrucous Carcinoma of the Oral Cavity / Stage IVA Colon Cancer / Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Colon Cancer / Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity / Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Tongue Cancer1
1CompletedTreatmentRefractory Malignancy1
1CompletedTreatmentRenal Cell Carcinoma (RCC)2
1CompletedTreatmentRhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Tumor, Brain / Tumors1
1CompletedTreatmentSarcomas / Tumors, Solid1
1CompletedTreatmentSmall-Cell Lung Cancer1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific3
1Not Yet RecruitingTreatmentMalignant Neoplasm of Breast / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Respiratory and Intrathoracic Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract / Neoplasms of Uncertain or Unknown Behavior1
1RecruitingTreatmentAdvanced Cancers2
1RecruitingTreatmentBreast Adenocarcinoma / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor-negative / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentCancer, Breast / Tumors, Solid1
1RecruitingTreatmentColorectal Cancers / Non-small Cell Lung Carcinoma (Adenocarcinoma) / Triple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentEsophageal Cancers1
1RecruitingTreatmentEverolimus / Neuroendocrine Tumors1
1RecruitingTreatmentFallopian Tube Cancer / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
1RecruitingTreatmentFumarate Hydratase (FH)-Deficient Tumors / Mesothelioma / Non Small Cell Lung Cancer (NSCLC) / Renal Cell Carcinoma (RCC) / Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) / Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors / Triple-Negative Breast Cancer (TNBC) / Tumors Harboring Amplifications in the cMyc Gene / Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations / Tumors, Solid1
1RecruitingTreatmentHead and Neck Cancers / Lung Cancers1
1RecruitingTreatmentMultiple Myeloma (MM) / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Chronic Lymphocytic Leukemia1
1RecruitingTreatmentNeoplasms, Breast1
1RecruitingTreatmentProstate Cancer Patients With Detectable PSA Following Prostatectomy1
1RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentRenal Cell Carcinoma Recurrent1
1RecruitingTreatmentTransplantation, Liver1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1TerminatedNot AvailableCancers1
1TerminatedTreatment714leukemia / Lymphoma NOS1
1TerminatedTreatmentCancer, Breast2
1TerminatedTreatmentGraft Versus Host Disease (GVHD)1
1TerminatedTreatmentHead and Neck Cancers2
1TerminatedTreatmentHepatocellular Carcinomas1
1TerminatedTreatmentLung Cancers / Metastatic Cancers1
1TerminatedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentMultiple Myeloma in Relapse1
1TerminatedTreatmentNeoplasm Metastases / Neuroendocrine Tumors / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Carcinoma (RCC)1
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1TerminatedTreatmentRenal Cell Carcinoma (RCC)1
1Unknown StatusTreatmentAcute Myeloid Leukaemias (AML)1
1Unknown StatusTreatmentLeukemias1
1Unknown StatusTreatmentLocally Advanced Disease / Non-Small-Cell Lung Carcinoma (NSCLC)1
1Unknown StatusTreatmentMetastatic or Locally Advanced Solid Tumors1
1WithdrawnTreatmentCervical Cancers1
1WithdrawnTreatmentLiver Cancer1
1WithdrawnTreatmentRecurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Tongue Cancer1
1, 2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / B-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Post-Transplant Lymphoproliferative Disorder / Primary Central Nervous System Non-Hodgkin Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Splenic Marginal Zone Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentBladder Cancers1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors2
1, 2Active Not RecruitingTreatmentCancer, Breast1
1, 2Active Not RecruitingTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2Active Not RecruitingTreatmentCentral Nervous System Metastases / HER2-positive Breast Cancer / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2Active Not RecruitingTreatmentGastric Cancers1
1, 2Active Not RecruitingTreatmentHistological Evidence of Metastatic Clear Cell Renal Cell Carcinoma / Metastatic Clear Cell Renal Cell Carcinoma / Of Discontinuing Sunitinib, Sorafenib or Pazopanib. Previous / That Has Been Previously Treated With 1-3 Prior Regimens. Phase 1 Only, Any Number of Prior Regimens / Therapy With Bevacizumab, IL2, or Interferon Are Permitted / With Evidence of Progressive Disease on or Within 6 Months1
1, 2Active Not RecruitingTreatmentLymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma1
1, 2Active Not RecruitingTreatmentPancreatic Neuroendocrine Tumors (pNET)1
1, 2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
1, 2CompletedTreatmentAcinar Cell Adenocarcinoma of the Pancreas / Duct Cell Adenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemias1
1, 2CompletedTreatmentAcute Myeloid Leukaemias (AML)1
1, 2CompletedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Diffuse Adenocarcinoma of the Stomach / Intestinal Adenocarcinoma of the Stomach / Mixed Adenocarcinoma of the Stomach / Recurrent Esophageal Cancer / Recurrent Gastric Cancer / Stage IV Esophageal Cancer / Stage IV Gastric Cancer1
1, 2CompletedTreatmentAdult Synovial Sarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
1, 2CompletedTreatmentAdvanced or Metastatic Pancreatic Adenocarcinoma1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma Unspecified1
1, 2CompletedTreatmentAngiolipoma / Tuberous Sclerosis1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Carcinoma of the Prostate1
1, 2CompletedTreatmentCD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentCancer, Breast / Neoplasms Metastasis1
1, 2CompletedTreatmentCancers of the Head and Neck / Neoplasms, Head and Neck1
1, 2CompletedTreatmentCarcinoma of the Prostate1
1, 2CompletedTreatmentCarcinoma of the Prostate / Metastatic, Androgen Independent Prostate Cancer1
1, 2CompletedTreatmentColorectal Cancers1
1, 2CompletedTreatmentEpilepsies / Tuberous Sclerosis Complex (TSC)1
1, 2CompletedTreatmentGastrointestinal Cancers1
1, 2CompletedTreatmentGastrointestinal Stromal Tumors1
1, 2CompletedTreatmentHead and Neck Cancers1
1, 2CompletedTreatmentHepatocellular Carcinomas1
1, 2CompletedTreatmentHypoglycemia / Type 1 Diabetes Mellitus (T1DM)1
1, 2CompletedTreatmentKidney Cancer1
1, 2CompletedTreatmentLeukemia, Lymphocytic1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Mantle Cell Lymphoma (MCL) / Myelofibrosis1
1, 2CompletedTreatmentLung Cancers1
1, 2CompletedTreatmentLymphangioleiomyomatosis / Tuberous Sclerosis1
1, 2CompletedTreatmentLymphoma NOS1
1, 2CompletedTreatmentMetastatic Gastric Cancers1
1, 2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentPancreatic Cancer Metastatic1
1, 2CompletedTreatmentRenal Cell Carcinoma (RCC)1
1, 2CompletedTreatmentSubependymal Giant Cell Astrocytoma / Tuberous Sclerosis1
1, 2Not Yet RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
1, 2Not Yet RecruitingTreatmentPTEN gene mutation / PTEN Hamartoma Tumor Syndrome1
1, 2RecruitingTreatmentAcute Coronary Syndromes (ACS)1
1, 2RecruitingTreatmentAdenocarcinomas / Neoplasms, Pancreatic1
1, 2RecruitingTreatmentAdult Living Donor Kidney Transplant Recipients / Living Kidney Donors / Renal Transplant / Transplant, Kidney1
1, 2RecruitingTreatmentAnaplastic Gliomas / Glioblastomas / Tumor, Brain1
1, 2RecruitingTreatmentCancer, Breast2
1, 2RecruitingTreatmentCarcinoma, Urothelial / Colorectal Adenocarcinoma (CRC) / Gastric Adenocarcinoma / Renal Cell Carcinoma (RCC)1
1, 2RecruitingTreatmentChildren, Adolescents and Young Adults With Refractory or Recurrent Malignancies1
1, 2RecruitingTreatmentHormone Receptor (HR)-Positive Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast1
1, 2RecruitingTreatmentLymphoma, Hodgkins1
1, 2RecruitingTreatmentMetastatic Renal Cell Cancer2
1, 2RecruitingTreatmentNeuroendocrine Carcinomas1
1, 2RecruitingTreatmentProgeria1
1, 2SuspendedTreatmentAdvanced Solid Tumors1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentCancer, Ovarian / Cancers / Colon Cancer / Neuroendocrine1
1, 2TerminatedTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2TerminatedTreatmentHead and Neck Cancers2
1, 2TerminatedTreatmentLiver Cancer1
1, 2TerminatedTreatmentLung Cancers1
1, 2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
1, 2TerminatedTreatmentNeoplasms1
1, 2TerminatedTreatmentPancreatic Cancers1
1, 2Unknown StatusTreatmentAdvanced Malignancies1
1, 2Unknown StatusTreatmentCancers1
1, 2Unknown StatusTreatmentCarcinoid Tumors / Neuroendocrine Tumors1
1, 2Unknown StatusTreatmentEnd-Stage Renal Disease (ESRD) / Kidney Failure1
1, 2Unknown StatusTreatmentHematologic Diseases1
1, 2Unknown StatusTreatmentHepatocellular Carcinomas1
1, 2WithdrawnTreatmentChronic Myeloid Leukemia (CML)1
2Active Not RecruitingPreventionGliomas1
2Active Not RecruitingTreatmentAdvanced, Persistent, or Recurrent Endometrial Cancer1
2Active Not RecruitingTreatmentBladder Cancers / Metastatic Transitional Cell Carcinoma1
2Active Not RecruitingTreatmentBladder Carcinoma / Carcinoma, Urothelial / Transitional Cell Carcinoma1
2Active Not RecruitingTreatmentCancer, Breast7
2Active Not RecruitingTreatmentCarcinoma of the Prostate1
2Active Not RecruitingTreatmentDifferentiated Thyroid Cancer (DTC)1
2Active Not RecruitingTreatmentEndometrial Cancers2
2Active Not RecruitingTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
2Active Not RecruitingTreatmentFibrolamellar Carcinoma / Fibrolamellar Liver Cancer1
2Active Not RecruitingTreatmentGastrin-Producing Neuroendocrine Tumor / Malignant Pancreatic Gastrinoma / Malignant Pancreatic Glucagonoma / Malignant Pancreatic Insulinoma / Malignant Pancreatic Somatostatinoma / Pancreatic Alpha Cell Adenoma / Pancreatic Beta Cell Adenoma / Pancreatic Delta Cell Adenoma / Pancreatic G-Cell Adenoma / Pancreatic Gastrinoma / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Neuroendocrine Tumor G1 / Pancreatic Neuroendocrine Tumor G2 / Pancreatic Polypeptide Tumor / Pancreatic Vipoma / Recurrent Pancreatic Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Somatostatin-Producing Neuroendocrine Tumor / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2Active Not RecruitingTreatmentHER-2 Positive Breast Cancer1
2Active Not RecruitingTreatmentHer2-negative Locally Advanced Breast Cancer / HER2-negative Metastatic Breast Cancer1
2Active Not RecruitingTreatmentHead and Neck Cancers2
2Active Not RecruitingTreatmentHepatic Metastases / Metastases / Neuroendocrine Tumors1
2Active Not RecruitingTreatmentHormone Receptor Positive Breast Cancer1
2Active Not RecruitingTreatmentKidney Cancer2
2Active Not RecruitingTreatmentMalignant Peripheral Nerve Sheath Tumors (MPNST) / MPNST / Sarcomas1
2Active Not RecruitingTreatmentMalignant Ovarian Mixed Epithelial Tumor / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Serous Surface Papillary Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Ovarian Carcinoma1
2Active Not RecruitingTreatmentMelanoma (Skin)1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)2
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentMetastatic Renal Cell Cancer / Recurrent Renal Cell Carcinoma / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma2
2Active Not RecruitingTreatmentMTOR Protein / Neoplasms, Breast1
2Active Not RecruitingTreatmentNeoplasms, Gastrointestinal1
2Active Not RecruitingTreatmentNeuroendocrine Carcinoma of the Lung and Thymus1
2Active Not RecruitingTreatmentNeurofibromatosis 21
2Active Not RecruitingTreatmentPediatric Progressive Low-grade Gliomas / Pediatric Recurrent Progressive Low-grade Gliomas1
2Active Not RecruitingTreatmentProgressive Sarcoma1
2Active Not RecruitingTreatmentRenal Cancers / Renal Cell Carcinoma (RCC)1
2Active Not RecruitingTreatmentRenal Cell Carcinoma (RCC)2
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Active Not RecruitingTreatmentThymoma and Thymic Carcinoma1
2Active Not RecruitingTreatmentThyroid Cancers2
2Active Not RecruitingTreatmentTransplantation, Kidney1
2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
2CompletedNot AvailableClear-cell Metastatic Renal Cell Carcinoma / Clear-cell Renal Carcinoma1
2CompletedPreventionAdvanced Breast Cancer1
2CompletedTreatmentAdenocarcinomas / Carcinomas / Hypernephroid / Nephroid Carcinoma / Renal Cell / Renal Cell Adenocarcinoma / Renal Cell Carcinoma (RCC)1
2CompletedTreatmentAdenocarcinomas / Carcinomas / Non Clear Cell Renal Carcinoma / Papillary Cell Renal Carcinoma / Renal Cell1
2CompletedTreatmentAdvanced Adult Hepatocellular Carcinoma1
2CompletedTreatmentAdvanced Non-clear Cell Renal Cell Carcinoma1
2CompletedTreatmentAstrocytomas / Gliomas / Low-Grade Gliomas1
2CompletedTreatmentAstrocytomas / Low-Grade Gliomas / Oligoastrocytoma, Mixed / Oligodendrogliomas1
2CompletedTreatmentAutism / Self-injury / Tuberous Sclerosis Complex (TSC)1
2CompletedTreatmentCancer, Breast4
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Carcinoma1
2CompletedTreatmentCarcinoids / Carcinomas / Neuroendocrine / Non Functioning / Non Functioning Neuroendocrine Tumors/NET / Non Syndromic Neuroendocrine Tumors/NET1
2CompletedTreatmentCarcinoma of Unknown Primary Origin1
2CompletedTreatmentCarcinoma of the Prostate2
2CompletedTreatmentCarcinoma, Adenoid Cystic1
2CompletedTreatmentCarcinoma, Islet Cell / Neoplasms, Pancreatic / Neuroendocrine Carcinomas / Neuroendocrine Tumors1
2CompletedTreatmentCarcinoma, Islet Cell / Neuroendocrine Carcinomas1
2CompletedTreatmentClear Cell Renal Carcinoma1
2CompletedTreatmentColorectal Adenocarcinoma1
2CompletedTreatmentColorectal Cancers2
2CompletedTreatmentCondition After Allogenic Peripheral Stem Cell Transplantation (SCT)1
2CompletedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2CompletedTreatmentEndometrial Cancers2
2CompletedTreatmentEsophageal Cancers / Gastric Cancers1
2CompletedTreatmentExtra-Adrenal Paraganglioma / Non-functioning Carcinoid / Pheochromocytomas1
2CompletedTreatmentGastric cancer stage IV1
2CompletedTreatmentGerm Cell Cancer / Testicular Cancer1
2CompletedTreatmentGerm Cell Tumors1
2CompletedTreatmentGlioblastoma Multiforme1
2CompletedTreatmentHead and Neck Cancers2
2CompletedTreatmentHepatocellular Carcinomas2
2CompletedTreatmentHormone Refractory Prostate Cancer1
2CompletedTreatmentKidney Cancer2
2CompletedTreatmentLeukemias / Lymphoma NOS / Lymphoproliferative Disorders1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLymphangioleiomyomatosis1
2CompletedTreatmentLymphoma NOS1
2CompletedTreatmentLymphoma, Hodgkins1
2CompletedTreatmentLymphoma, Mantle- Cell1
2CompletedTreatmentMalignant Pleural Mesothelioma (MPM)1
2CompletedTreatmentMarginal Zone B-Cell Lymphoma1
2CompletedTreatmentMelanoma (Skin)2
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Colorectal Cancers1
2CompletedTreatmentMetastatic Gastric Cancers1
2CompletedTreatmentMetastatic Melanoma2
2CompletedTreatmentMetastatic Osteosarcoma / Relapsed Osteosarcoma1
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNeuroendocrine Carcinomas1
2CompletedTreatmentNeurofibromatoses / Neurofibromatosis Type 1 / Plexiform Neurofibroma1
2CompletedTreatmentNeurofibromatosis 11
2CompletedTreatmentNeurofibromatosis Type II1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentPancreatic Cancers1
2CompletedTreatmentPolycystic Liver Disease (PLD)1
2CompletedTreatmentRenal Cell Carcinoma (RCC)5
2CompletedTreatmentSarcoma, Bone / Soft Tissue Sarcoma (STS)1
2CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
2CompletedTreatmentStomach Neoplasms2
2CompletedTreatmentSystemic Mastocytosis1
2CompletedTreatmentTransitional Cell Carcinoma1
2CompletedTreatmentTransplantation, Kidney1
2CompletedTreatmentTransplantation, Renal1
2CompletedTreatmentTuberous Sclerosis Complex (TSC)1
2CompletedTreatmentTumors, Solid1
2CompletedTreatmentUrothelial Cancer1
2CompletedTreatmentUveal Melanoma1
2CompletedTreatmentUveitis1
2Not Yet RecruitingTreatmentEndometrial Carcinoma / Malignant Neoplasms of Female Genital Organs1
2Not Yet RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentTuberculosis1
2RecruitingPreventionGraft Versus Host Disease (GVHD)1
2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Neoplasms / Neoplasms, Advanced Solid / Recurrent Malignant Solid Neoplasm / Recurrent Solid Neoplasm1
2RecruitingTreatmentBirt-Hogg-Dube Syndrome / Chromophobe Renal Cell Carcinoma / Renal Cancers1
2RecruitingTreatmentBreast Cancer Stage IIB1
2RecruitingTreatmentCD20+, B-cell Lymphomas / Gray Zone Lymphoma / Hodgkins Disease (HD) / Mantle Cell Lymphoma (MCL) / Non-Mantle Cell Low Grade B Cell Lymphomas (SLL/CLL) / Transformed Lymphoma/DLBCL/PMBCL1
2RecruitingTreatmentCancer, Breast3
2RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2RecruitingTreatmentCancer, Ovarian / Endometrial Cancers1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCholangiocarcinoma of the Extrahepatic Bile Duct / Gallbladder Cancer1
2RecruitingTreatmentClear-cell Metastatic Renal Cell Carcinoma1
2RecruitingTreatmentDiffuse Intrinsic Pontine Glioma (DIPG)1
2RecruitingTreatmentEndometrial Cancers1
2RecruitingTreatmentEpilepsies / Focal Cortical Dysplasia / Tuberous Sclerosis Complex (TSC)1
2RecruitingTreatmentEstrogen Receptor Positive Breast Cancer1
2RecruitingTreatmentGastrointestinal Neuroendocrine Tumors / Gastrointestinal Tumors / Pancreatic Neuroendocrine Tumors (pNET) / Pancreatic Tumors1
2RecruitingTreatmentHER2-negative Circulating Tumor Cells / HER2-negative Und Hormone-receptor Positive Metastatic Breast Cancer / Postmenopausal Female Patients1
2RecruitingTreatmentLow Grade Glioma (LGG) / Oligoastrocytoma, Mixed / Oligodendrogliomas / WHO Grade II Astrocytomas1
2RecruitingTreatmentMalignant Solid Neoplasms1
2RecruitingTreatmentMelanoma / Neoplasms Metastasis / TOR Serine-Threonine Kinases1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentMetastatic Renal Cancer1
2RecruitingTreatmentNeoplasms1
2RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentNeuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 / Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3 / Neuroendocrine Carcinoma, Grade 3 / Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) / Poorly Differentiated Malignant Neuroendocrine Carcinoma / Poorly Differentiated Neuroendocrine Carcinoma1
2RecruitingTreatmentNeuroendocrine Carcinomas3
2RecruitingTreatmentNeuroendocrine Tumors2
2RecruitingTreatmentNeurofibromatosis Type 2 / Neuroma, Acoustic1
2RecruitingTreatmentNon Clear Cell Renal Cell Carcinoma (nccRCC)1
2RecruitingTreatmentOrthotopic Liver Transplant1
2RecruitingTreatmentRecurrent Childhood Ependymoma1
2RecruitingTreatmentRecurrent Meningiomas / Resistant Meningiomas1
2RecruitingTreatmentRefractory Hurthle Cell Thyroid Cancer1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2RecruitingTreatmentRenal Cell Carcinoma (RCC)1
2RecruitingTreatmentSolid Malignancies / Tumors, Solid1
2RecruitingTreatmentSporadic Angiomyolipomas (AMLs)1
2RecruitingTreatmentMTOR / TSC1 / TSC2 / Tuberous Sclerosis Complex (TSC)1
2RecruitingTreatmentTransplantation, Kidney1
2RecruitingTreatmentTuberous Sclerosis1
2RecruitingTreatmentTumor, Brain1
2SuspendedTreatmentChondrosarcomas1
2TerminatedPreventionKidney Cancer1
2TerminatedTreatmentAge-Related Macular Degeneration (ARMD) / Choroidal Neo-Vascular Age-onset Macular Degeneration1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentCarcinoma of the Prostate1
2TerminatedTreatmentCarcinoma of the Prostate / Castrate Resistant Prostate Cancer (CRPC) / Chemotherapy Naive Prostate Cancer1
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentCutaneous T-Cell Lymphoma (CTCL)1
2TerminatedTreatmentDiffuse Large B-Cell Lymphoma (DLBCL)1
2TerminatedTreatmentEndocrine Breast Diseases / Neoplasms Metastasis / Neoplasms, Breast1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / Gastrinoma / Glucagonoma / HER2-Negative Breast Cancer / Insulinoma / Mucositis / Oral Complications / Pancreatic Polypeptide Tumor / Progesterone Receptor-positive Breast Cancer / Recurrent Breast Cancer / Recurrent Islet Cell Carcinoma / Recurrent Renal Cell Cancer / Somatostatinoma / Stage III Renal Cell Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Stage IV Renal Cell Cancer1
2TerminatedTreatmentGastrinoma / Glucagonoma / Insulinoma / Liver Metastases / Pancreatic Polypeptide Tumor / Recurrent Islet Cell Carcinoma / Somatostatinoma1
2TerminatedTreatmentGlioblastoma Multiforme1
2TerminatedTreatmentIntracranial Meningioma1
2TerminatedTreatmentIslet Cell Tumor1
2TerminatedTreatmentKaposi s Sarcoma (KS)1
2TerminatedTreatmentKidney (Renal Cell) Cancer / Neoplasms, Kidney1
2TerminatedTreatmentKidney Cancer1
2TerminatedTreatmentLymphoma NOS1
2TerminatedTreatmentMetastatic Clear Cell Renal Carcinoma1
2TerminatedTreatmentMetastatic Melanoma1
2TerminatedTreatmentMyelodysplastic Syndromes1
2TerminatedTreatmentPancreatic Cancers1
2TerminatedTreatmentPancreatic Neuroendocrine Tumors (pNET)1
2TerminatedTreatmentPeutz-Jeghers Syndrome1
2TerminatedTreatmentPlexiform Neurofibroma Associated With Neurofibromatosis Type 11
2TerminatedTreatmentRecurrent Hepatitis C1
2TerminatedTreatmentSarcomas1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2Unknown StatusTreatmentCarcinoma of the Prostate2
2Unknown StatusTreatmentCholangiocarcinomas2
2Unknown StatusTreatmentChronic Renal Insufficiency / Transplantation, Liver1
2Unknown StatusTreatmentHead and Neck Cancers1
2Unknown StatusTreatmentHormone Receptor Positive Malignant Neoplasm of Breast1
2Unknown StatusTreatmentKidney Diseases1
2Unknown StatusTreatmentLiver Cirrhosis / Liver Diseases / Liver Failure / Neoplasms, Liver1
2Unknown StatusTreatmentMesothelioma, Malignant1
2Unknown StatusTreatmentMetastatic Renal Cell Carcinoma1
2Unknown StatusTreatmentNeoplasms, Breast1
2Unknown StatusTreatmentNeuroendocrine Tumors1
2Unknown StatusTreatmentRefractory or Relapsed Osteosarcoma1
2Unknown StatusTreatmentRefractory or Relapsed RMS and Soft Tissue Sarcomas1
2WithdrawnTreatmentCancer, Breast3
2WithdrawnTreatmentLocally Metastatic Malignant Neoplasm1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2WithdrawnTreatmentNeoplasms Metastasis / Neoplastic Processes / Peutz-Jeghers Syndrome1
2WithdrawnTreatmentSegmental Overgrowth Syndrome1
2WithdrawnTreatmentSturge Weber Syndrome1
2, 3Not Yet RecruitingTreatmentFacial Angiofibromas1
2, 3Not Yet RecruitingTreatmentRenal Cell Cancer Metastatic1
2, 3RecruitingTreatmentDelayed Graft Function1
2, 3RecruitingTreatmentTSC Related Autism / TSC Related Cognitive Disability / TSC Related Learning Problems / Tuberous Sclerosis Complex (TSC)1
2, 3TerminatedTreatmentGraft Versus Host Disease (GVHD)1
2, 3TerminatedTreatmentPolycystic Kidney Diseases1
3Active Not RecruitingTreatmentAdvanced NET of GI Origin / Advanced NET of Lung Origin / Neuroendocrine Tumors1
3Active Not RecruitingTreatmentAdvanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma1
3Active Not RecruitingTreatmentCancer, Breast2
3Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Carcinoma / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
3Active Not RecruitingTreatmentEsophagogastric Junction Cancer / Gastric cancer stage IV1
3Active Not RecruitingTreatmentKidney Cancer1
3Active Not RecruitingTreatmentPrevention of Acute Rejection in Paediatric Recipients of a Renal Transplant1
3Active Not RecruitingTreatmentRenal Cell Carcinoma (RCC)1
3Active Not RecruitingTreatmentTransplantation, Lung1
3Active Not RecruitingTreatmentTuberous Sclerosis Complex-associated Refractory Seizures1
3CompletedBasic ScienceHepatitis C Recurrence After Liver Transplant1
3CompletedPreventionCardiac Transplantation1
3CompletedPreventionDe Novo Kidney Transplant Recipients / Transplantation, Renal1
3CompletedPreventionDiffuse Large B-Cell Lymphoma (DLBCL)1
3CompletedPreventionGraft Rejection1
3CompletedPreventionHeart Transplantation1
3CompletedPreventionTransplantation, Kidney2
3CompletedPreventionTransplantation, Renal3
3CompletedTreatmentAdvanced Neuroendocrine Tumors of Pancreatic Origin1
3CompletedTreatmentCancer, Breast2
3CompletedTreatmentCarcinoid Tumors / Malignant Carcinoid Syndrome1
3CompletedTreatmentCarcinomas1
3CompletedTreatmentDe Novo Renal Transplantation1
3CompletedTreatmentGastric cancer stage IV1
3CompletedTreatmentGraft Rejection1
3CompletedTreatmentGraft Rejection / Transplantation, Kidney1
3CompletedTreatmentHER2/Neu Over-expressing Locally Advanced Breast Cancer / Metastatic Breast Cancer (MBC)1
3CompletedTreatmentHeart Transplantation1
3CompletedTreatmentLiver Transplant Recipients1
3CompletedTreatmentLymphangioleiomyomatosis (LAM) / Tuberous Sclerosis Complex (TSC)1
3CompletedTreatmentMetastatic Breast Cancer (MBC)1
3CompletedTreatmentMetastatic Renal Cell Carcinoma1
3CompletedTreatmentOrgan Transplantation, Renal Transplantation1
3CompletedTreatmentRenal Interstitial Fibrosis1
3CompletedTreatmentRenal Transplant1
3CompletedTreatmentSubependymal Giant Cell Astrocytoma / Tuberous Sclerosis1
3CompletedTreatmentTransplant, Kidney1
3CompletedTreatmentTransplant; Failure, Kidney1
3CompletedTreatmentTransplantation, Kidney2
3CompletedTreatmentTransplantation, Liver4
3CompletedTreatmentTransplantation, Lung1
3CompletedTreatmentTransplantation, Renal2
3Not Yet RecruitingPreventionTransplantation, Liver1
3Not Yet RecruitingTreatmentTuberous Sclerosis Complex (TSC)1
3RecruitingTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3RecruitingTreatmentBreast Cancer Metastatic1
3RecruitingTreatmentCancer, Breast2
3RecruitingTreatmentCancer, Breast / Hormone Receptor Positive Tumor / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Locally Advanced Malignant Neoplasm / Metastatic Breast Cancer (MBC)1
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3RecruitingTreatmentNeuroendocrine Tumors1
3RecruitingTreatmentPancreatic Neuroendocrine Tumors (pNET)1
3RecruitingTreatmentPrimary Non-metastatic Breast Cancer / Who Remain Disease-free / Who Remain Disease-free After Receiving at Least 1 Year of Adjuvant Hormone Therapy1
3RecruitingTreatmentRenal Cell Carcinoma (RCC)1
3RecruitingTreatmentTransplantation, Liver1
3TerminatedTreatmentKidney Failure,Chronic1
3TerminatedTreatmentMetastatic Breast Cancer (MBC)1
3Unknown StatusTreatmentCardiac Transplantation / Skin Cancers1
3Unknown StatusTreatmentCoronary Artery Disease / Coronary Artery Restenosis1
4Active Not RecruitingNot AvailableGrowth and Development1
4Active Not RecruitingPreventionInfections, Cytomegalovirus / Transplantation Infection1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis / Renal Replacement Therapies / Transplantation, Renal1
4Active Not RecruitingTreatmentCytomegalovirus / Transplantation, Kidney1
4Active Not RecruitingTreatmentFailure of Exactly One Prior VEGF-targeted Therapy / Metastatic Renal Cell Carcinoma1
4Active Not RecruitingTreatmentGraft Dysfunction / Interstitial Fibrosis (IF)1
4Active Not RecruitingTreatmentHeart Transplantation1
4Active Not RecruitingTreatmentOestrogen Receptor Positive Advanced Breast Cancer1
4Active Not RecruitingTreatmentPancreatic Neuroendocrine Tumors (pNET)1
4CompletedNot AvailableFunction of Renal Transplant1
4CompletedDiagnosticHeart Transplant1
4CompletedOtherTransplant, Kidney1
4CompletedPreventionCardiac Transplantation1
4CompletedPreventionChronic Rejection of Cardiac Transplant1
4CompletedPreventionDisorder Related to Cardiac Transplantation1
4CompletedPreventionHeart Transplantation1
4CompletedPreventionTransplantation, Kidney1
4CompletedPreventionTransplantation, Renal3
4CompletedSupportive CareHepatitis C / Renal Allograft1
4CompletedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
4CompletedTreatmentBK Virus Infection1
4CompletedTreatmentCarcinoma, Large Cell / Neuroendocrine Tumors1
4CompletedTreatmentChronic Allograft Dysfunction in Renal Transplantation1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentComparative Study / Immunosuppressive Agents1
4CompletedTreatmentInfections, Cytomegalovirus / Renal Transplant Failure / Transplant; Complication, Rejection1
4CompletedTreatmentKidney Transplantation, Renal Transplantation1
4CompletedTreatmentMetastatic Renal Cell Carcinoma1
4CompletedTreatmentMetastatic Renal Cell Carcinoma (mRCC)1
4CompletedTreatmentNeuroendocrine Tumors1
4CompletedTreatmentPlanned Kidney Transplantation1
4CompletedTreatmentRenal Function1
4CompletedTreatmentRenal Function and Chronic Allograft Vasculopathy1
4CompletedTreatmentRenal Transplant1
4CompletedTreatmentRenal Transplanted Recipients1
4CompletedTreatmentTransplantation, Kidney1
4CompletedTreatmentTransplantation, Organ1
4CompletedTreatmentTransplantation, Renal3
4Not Yet RecruitingTreatmentDisorder Related to Renal Transplantation / Immunosuppression Related Infectious Disease / Virus Diseases1
4Not Yet RecruitingTreatmentGastrointestinal Disorder, Functional / Kidney Transplant Rejection1
4Not Yet RecruitingTreatmentHeart Transplantation1
4RecruitingNot AvailableBreast Cancer Recurrent / HER2/Neu-negative Carcinoma of Breast / Hormone Receptor Positive Malignant Neoplasm of Breast1
4RecruitingNot AvailableKidney Failure1
4RecruitingNot AvailableLeft Ventricular Hypertrophy1
4RecruitingBasic ScienceHIV Disease / Liver Transplant / Transplant, Kidney1
4RecruitingTreatmentChronic Renal Failure (CRF) / Graft Failure / Renal Transplant Rejection / Transplant; Failure, Kidney1
4RecruitingTreatmentDrug Interaction Potentiation / Transplantation, Kidney1
4RecruitingTreatmentHepatocellular Carcinomas1
4RecruitingTreatmentInfections, Cytomegalovirus / Transplantation Infection1
4RecruitingTreatmentLocally Advanced Metastatic Breast Cancer / Locally Advanced or Metastatic Breast Cancer / Metastatic Breast Cancer (MBC) / Postmenopausal Women1
4RecruitingTreatmentNeoplasms1
4RecruitingTreatmentRenal Cell Carcinoma (RCC)1
4RecruitingTreatmentRenal Transplant1
4TerminatedNot AvailableRenal Cell Carcinoma (RCC)1
4TerminatedBasic ScienceDisorder Related to Renal Transplantation / Exercise, Aerobic / Strength, Muscle1
4TerminatedPreventionHeart Transplantation / Kidney Dysfunction1
4TerminatedPreventionRenal Insufficiency1
4TerminatedPreventionTransplantation, Renal1
4TerminatedTreatmentTransplantation, Renal2
4Unknown StatusPreventionDisorder Related to Renal Transplantation1
4Unknown StatusPreventionHeart Transplantation / Kidney Diseases1
4Unknown StatusPreventionImmunosuppression / Transplantation, Homologous1
4Unknown StatusPreventionKidney Transplant Recipients1
4Unknown StatusPreventionKidney; Complications, Allograft1
4Unknown StatusTreatmentCardiac Transplant1
4Unknown StatusTreatmentCardiac Transplantation / Chronic Renal Insufficiency1
4Unknown StatusTreatmentDelayed Function of Renal Transplant1
4Unknown StatusTreatmentImmunosuppression / Transplant, Kidney1
4Unknown StatusTreatmentInfections, Cytomegalovirus1
4Unknown StatusTreatmentTransplantation, Renal1
4WithdrawnNot AvailableTransplantation, Kidney1
4WithdrawnTreatmentTransplantation, Kidney1
Not AvailableActive Not RecruitingDiagnosticAdvanced Solid Tumors / Cancers1
Not AvailableActive Not RecruitingOtherHormone Receptor Positive Malignant Neoplasm of Breast / Metastatic Breast Cancer (MBC)1
Not AvailableActive Not RecruitingPreventionRenal Failure1
Not AvailableActive Not RecruitingTreatmentEnd Stage Renal Failure With Renal Transplant1
Not AvailableActive Not RecruitingTreatmentRecurrent Childhood Brain Tumor1
Not AvailableActive Not RecruitingTreatmentRenal Cell Carcinoma (RCC)1
Not AvailableCompletedNot AvailableCancer, Breast1
Not AvailableCompletedNot AvailableCancer, Breast / Renal Cell Carcinoma (RCC)1
Not AvailableCompletedNot AvailableNeuroendocrine Tumors1
Not AvailableCompletedBasic ScienceDifference of 12-hour AUC1
Not AvailableCompletedTreatmentHigh Model for End-Stage Liver Disease (MELD) Score1
Not AvailableCompletedTreatmentTransplantation, Kidney1
Not AvailableNo Longer AvailableNot AvailableMetastatic Renal Cell Cancer1
Not AvailableRecruitingNot AvailableHepatocellular Carcinomas / Neuroendocrine Tumors1
Not AvailableRecruitingNot AvailableLymphangioleiomyomatosis1
Not AvailableRecruitingNot AvailablePancreatic Neuroendocrine Tumor, Well Differentiated and Progressive1
Not AvailableRecruitingBasic ScienceNeoplasms1
Not AvailableRecruitingTreatmentGastrointestinal Cancers1
Not AvailableRecruitingTreatmentImmunosuppression1
Not AvailableTerminatedTreatmentEnd Stage Renal Failure With Renal Transplant1
Not AvailableUnknown StatusNot AvailableUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableUnknown StatusTreatmentCalcineurin Inhibitor Toxicity / Chronic Allograft Injury1
Not AvailableUnknown StatusTreatmentRenal Transplant1
Not AvailableUnknown StatusTreatmentMicroRNA Profiles1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral10 mg
TabletOral2.5 mg/1
TabletOral2.5 mg
TabletOral5 mg/1
TabletOral5 mg
TabletOral7.5 mg/1
TabletOral7.5 mg
Tablet, for suspensionOral2 mg/1
Tablet, for suspensionOral2 mg
Tablet, for suspensionOral3 mg
Tablet, for suspensionOral3 mg/1
Tablet, for suspensionOral5 mg
Tablet, for suspensionOral5 mg/1
TabletOral0.25 mg
TabletOral0.50 mg
TabletOral0.75 mg
TabletOral.25 mg/1
TabletOral.5 mg/1
TabletOral.75 mg/1
Prices
Unit descriptionCostUnit
Afinitor 10 mg tablet247.58USD tablet
Afinitor 5 mg tablet234.75USD tablet
Vesicare 10 mg tablet6.98USD tablet
Vesicare 5 mg tablet6.98USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2145383 No2004-11-162013-09-24Canada
CA2225960 No2004-05-112016-07-12Canada
US5665772 Yes2000-03-092020-03-09Us
US6004973 Yes1997-01-122017-01-12Us
US6239124 Yes1998-02-112018-02-11Us
US6440990 No1993-09-242013-09-24Us
US6455518 Yes1998-01-292018-01-29Us
US7297703 Yes2000-06-062020-06-06Us
US7741338 No1999-12-062019-12-06Us
US8410131 Yes2006-05-012026-05-01Us
US8436010 Yes2002-08-222022-08-22Us
US8617598 Yes2003-03-272023-03-27Us
US8778962 Yes2002-08-182022-08-18Us
US9006224 No2008-07-012028-07-01Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00163 mg/mLALOGPS
logP5.01ALOGPS
logP7.4ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area204.66 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity261.71 m3·mol-1ChemAxon
Polarizability106.61 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8288
Blood Brain Barrier-0.9541
Caco-2 permeable-0.6604
P-glycoprotein substrateSubstrate0.8117
P-glycoprotein inhibitor IInhibitor0.7789
P-glycoprotein inhibitor IIInhibitor0.7294
Renal organic cation transporterNon-inhibitor0.796
CYP450 2C9 substrateNon-substrate0.8793
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9078
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9388
CYP450 2C19 inhibitorNon-inhibitor0.9346
CYP450 3A4 inhibitorNon-inhibitor0.8168
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9734
Ames testNon AMES toxic0.6227
CarcinogenicityNon-carcinogens0.9362
BiodegradationNot ready biodegradable0.9257
Rat acute toxicity2.7442 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9776
hERG inhibition (predictor II)Non-inhibitor0.712
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Download (87.7 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as macrolide lactams. These are cyclic polyketides containing both a cyclic amide and a cyclic ester group.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassMacrolide lactams
Sub ClassNot Available
Direct ParentMacrolide lactams
Alternative Parents
Substituents
  • Macrolide lactam
  • Alpha-amino acid ester
  • Macrolide
  • Alpha-amino acid or derivatives
  • Piperidine
  • Oxane
  • Tertiary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid ester
  • Hemiacetal
  • Ketone
  • Lactam
  • Cyclic ketone
  • Secondary alcohol
  • Lactone
  • Carboxylic acid derivative
  • Dialkyl ether
  • Ether
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxygen compound
  • Carbonyl group
  • Organic oxide
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tfiiic-class transcription factor binding
Specific Function:
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2). Activ...
Gene Name:
MTOR
Uniprot ID:
P42345
Molecular Weight:
288889.05 Da
References
  1. Ettenger R, Hoyer PF, Grimm P, Webb N, Loirat C, Mahan JD, Mentser M, Niaudet P, Offner G, Vandamme-Lombaerts R, Hexham JM: Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. Pediatr Transplant. 2008 Jun;12(4):456-63. doi: 10.1111/j.1399-3046.2007.00832.x. [PubMed:18466433 ]
  2. Rostaing L, Kamar N: mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol. 2010 Mar-Apr;23(2):133-42. [PubMed:20155724 ]
  3. George S, Bukowski RM: Role of everolimus in the treatment of renal cell carcinoma. Ther Clin Risk Manag. 2009 Oct;5(5):699-706. Epub 2009 Sep 15. [PubMed:19774211 ]
  4. Teachey DT, Grupp SA, Brown VI: Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol. 2009 Jun;145(5):569-80. doi: 10.1111/j.1365-2141.2009.07657.x. Epub 2009 Mar 16. [PubMed:19344392 ]
  5. Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E: New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. [PubMed:20569080 ]
  6. Coppin C: Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics. 2010 May 25;4:91-101. [PubMed:20531964 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 09:37 / Updated on April 22, 2017 06:24